Weifeng Liu

Weifeng Liu

Auto-generated profile, based on publicly available information

Weifeng Liu

Department of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
WLWeifeng Liu
Weifeng Liu
TCTing-Fang Chou
Ting-Fang Chou
SGSarah C. Garrett-Thomson
Sarah C. Garrett-Thomson
GSGoo-Young Seo
Goo-Young Seo
EFElena Fedorov
Elena Fedorov
SASteven C Almo
Steven C Almo
HVEM is a TNF (tumor necrosis factor) receptor contributing to a broad range of immune functions involving diverse cell types. It interacts with a TNF ligand, LIGHT, and immunoglobulin (Ig) superfamily members BTLA and CD160. Assessing the functional impact of HVEM binding to specific ligands in different settings has been complicated by the multiple interactions of HVEM and HVEM binding partners. To dissect the molecular basis for multiple functions, we determined crystal structures that reveal the distinct HVEM surfaces that engage LIGHT or BTLA/CD160, including the human HVEM–LIGHT–CD160 ternary complex, with HVEM interacting simultaneously with both binding partners. Based on these structures, we generated mouse HVEM mutants that selectively recognized either the TNF or Ig ligands in vitro. Knockin mice expressing these muteins maintain expression of all the proteins in the HVEM network, yet they demonstrate selective functions for LIGHT in the clearance of bacteria in the intestine and for the Ig ligands in the amelioration of liver inflammation.

1 October 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
WLWeifeng Liu
Weifeng Liu
ZMZachary Maben
Zachary Maben
CWCarole Wang
Carole Wang
KLKevin C. Lindquist
Kevin C. Lindquist
MLManqing Li
Manqing Li
JCJavier Chaparro-Riggers
Javier Chaparro-Riggers
CD27 is a tumor necrosis factor (TNF) receptor, which stimulates lymphocytes and promotes their differentiation upon activation by TNF ligand CD70. Activation of the CD27 receptor provides a costimulatory signal to promote T cell, B cell, and NK cell activity to facilitate antitumor and anti-infection immunity. Aberrant increased and focused expression of CD70 on many tumor cells renders CD70 an attractive therapeutic target for direct tumor killing. However, despite their use as drug targets to treat cancers, the molecular basis and atomic details of CD27 and CD70 interaction remain elusive. Here we report the crystal structure of human CD27 in complex with human CD70. Analysis of our structure shows that CD70 adopts a classical TNF ligand homotrimeric assembly to engage CD27 receptors in a 3:3 stoichiometry. By combining structural and rational mutagenesis data with reported disease-correlated mutations, we identified the key amino acid residues of CD27 and CD70 that control this interaction. We also report increased potency for plate-bound CD70 constructs compared with solution-phase ligand in a functional activity to stimulate T-cells in vitro. These findings offer new mechanistic insight into this critical costimulatory interaction.

13 August 2020 in Structure
Verified
Journal Article
Closed access
RSRojan Shrestha
Rojan Shrestha
SGSarah C. Garrett-Thomson
Sarah C. Garrett-Thomson
WLWeifeng Liu
Weifeng Liu
SASteven C Almo
Steven C Almo
AFAndras Fiser
Andras Fiser

13 November 2021 in Current Research in Structural Biology
Verified
Journal Article
Open access
RSRojan Shrestha
Rojan Shrestha
SGSarah Garrett-Thomson
Sarah Garrett-Thomson
WLWeifeng Liu
Weifeng Liu
SASteven C. Almo
Steven C. Almo
AFAndras Fiser
Andras Fiser
Molecular interactions mediated by engagement of the Herpes virus entry mediator (HVEM) with members of TNF and Ig superfamily generate distinct signals in T cell activation pathways that modulate inflammatory and inhibitory responses. HVEM interacts with CD160 and B and T lymphocyte attenuator (BTLA), both members of the immunoglobulin (Ig) superfamily, which share a common binding site that is unique from that of LIGHT, a TNF ligand. BTLA or CD160 engagement with HVEM deliver inhibitory or stimulatory signals to the host immune response in a context dependent fashion, whereas HVEM engagement with LIGHT results in pro-inflammatory responses. We identified a mutation in human HVEM, G89F, which directly interferes with the human LIGHT interaction, but interestingly, also differentially modulates the binding of human BTLA and CD160 via an apparent allosteric mechanism involving recognition surfaces remote from the site of the mutation. Specifically, the G89F mutation enhances binding of CD160, while decreasing that of BTLA to HVEM in cell-based assays. Molecular dynamics simulations for wild-type and G89F mutant HVEM, bound to different sets of ligands, were performed to define the molecular basis of this unexpected allosteric effect. These results were leveraged to design additional human HVEM mutants with altered binding specificities.